Grant: Collaborative Health Research Projects (NSERC partnered)
University of Toronto
$235,413.00
Vascularized regenerative biomaterials for medical devices and cell therapy
EF 2015-16
Résumé
While islet transplantation is a promising treatment for the 1% of Canadians who live with insulin dependent (type 1) diabetes, the majority of islets (perhaps 60%) in current protocols are lost almost immediately upon transplantation. This is due to inflammatory responses and the lack of blood vessels near the islet which impairs islet survival and function. We have discovered a unique material that induces the formation of blood vessels and we propose to use this material (as a "coating" or as an degradable gel) to generate a medical device (particularly a cell delivery device) that is more functional than is currently attainable with conventional materials. The successful use of implantable medical devices is built on the biocompatibility of inert biomaterials that generate a fibrotic response which isolates the implant from the patient and ensures the device is safe. However, this fibrosis precludes the successful use of other devices such as glucose sensors or cell pouches for cell delivery (especially pancreatic islets for diabetes). In this proposal the focus is on a unique Cell Pouch System produced by an Ontario company, Sernova which is being developed for pancreatic islet delivery to treat diabetes. The unique vascular regenerating biomaterial, based on MAA (methacrylic acid) is expected to enhance vascularization in and around the pouch and so accelerate the ability of islets to respond to elevated glucose levels in diabetic patients. Furthermore the MAA materials (and particularly the degradable gel) are expected to simplify the clinical use (and efficacy of the Cell Pouch because it is expected that the device can be implanted and loaded with islets in one step..
Programme
Collaborative Health Research Projects (NSERC partnered)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
336771
Name
Sefton Michael V
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Vascularized regenerative biomaterials for medical devices and cell therapy
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$235,413
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Cell Pouch; Diabetes; Injectable Gel; Islet Transplantation; Vascularization
Abstract
While islet transplantation is a promising treatment for the 1% of Canadians who live with insulin dependent (type 1) diabetes, the majority of islets (perhaps 60%) in current protocols are lost almost immediately upon transplantation. This is due to inflammatory responses and the lack of blood vessels near the islet which impairs islet survival and function. We have discovered a unique material that induces the formation of blood vessels and we propose to use this material (as a "coating" or as an degradable gel) to generate a medical device (particularly a cell delivery device) that is more functional than is currently attainable with conventional materials. The successful use of implantable medical devices is built on the biocompatibility of inert biomaterials that generate a fibrotic response which isolates the implant from the patient and ensures the device is safe. However, this fibrosis precludes the successful use of other devices such as glucose sensors or cell pouches for cell delivery (especially pancreatic islets for diabetes). In this proposal the focus is on a unique Cell Pouch System produced by an Ontario company, Sernova which is being developed for pancreatic islet delivery to treat diabetes. The unique vascular regenerating biomaterial, based on MAA (methacrylic acid) is expected to enhance vascularization in and around the pouch and so accelerate the ability of islets to respond to elevated glucose levels in diabetic patients. Furthermore the MAA materials (and particularly the degradable gel) are expected to simplify the clinical use (and efficacy of the Cell Pouch because it is expected that the device can be implanted and loaded with islets in one step..
Competitiondate
201510
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Sefton, Michael V; Cattral, Mark S
Approvedterm
3 ans 0 mois
Cihrcontribution2
Major Initiatives #2~ $235,413~ $0~